Insights

Innovative RNA Focus Arrakis Therapeutics specializes in pioneering small-molecule drugs that target RNA, positioning it at the forefront of a rapidly emerging field with high potential for developing first-in-class therapies. This creates opportunities for collaboration and licensing with biopharma companies seeking novel RNA-targeted treatments.

Strategic Collaborations The company has established significant partnerships, notably with Amgen, to develop RNA degrader therapeutics, indicating openness to licensing agreements, co-development, or supply partnerships that could accelerate market entry of new medicines.

Growing Investment With substantial funding of $75 million and revenue estimates between $10 and $50 million, Arrakis is expanding its capabilities, offering opportunities for sales of research tools, early-stage technology licenses, and contract research services.

Targeting Undruggable Space Arrakis’s focus on unlocking previously inaccessible biological targets opens avenues for customized services or products aimed at biotech firms and drug developers interested in expanding their pipeline into RNA biology.

Expanding Scientific Footprint Participation in prominent scientific events like MDA Conference 2025 and their innovative research enables connections with research institutions and biotech companies looking for cutting-edge RNA platform technologies to enhance their drug discovery efforts.

Arrakis Therapeutics Tech Stack

Arrakis Therapeutics uses 8 technology products and services including Cloudflare, MixItUp, jQuery UI, and more. Explore Arrakis Therapeutics's tech stack below.

  • Cloudflare
    Content Management System
  • MixItUp
    Javascript Frameworks
  • jQuery UI
    Javascript Libraries
  • Slick
    Javascript Libraries
  • Microsoft
    Miscellaneous
  • Microsoft Exchange
    Storage
  • Google Analytics
    Web Analytics
  • jQuery Waypoints
    Web Tools And Plugins

Media & News

Arrakis Therapeutics's Email Address Formats

Arrakis Therapeutics uses at least 1 format(s):
Arrakis Therapeutics Email FormatsExamplePercentage
FLast@arrakistx.comJDoe@arrakistx.com
94%
Last@arrakistx.comDoe@arrakistx.com
4%
FMLast@arrakistx.comJMDoe@arrakistx.com
1%
FirLast@arrakistx.comJohDoe@arrakistx.com
1%

Frequently Asked Questions

Where is Arrakis Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Arrakis Therapeutics's main headquarters is located at 828 Winter Street, Waltham, MA 02451, US. The company has employees across 4 continents, including North AmericaEuropeOceania.

What is Arrakis Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Arrakis Therapeutics's official website is arrakistx.com and has social profiles on LinkedInCrunchbase.

What is Arrakis Therapeutics's NAICS code?

Minus sign iconPlus sign icon
Arrakis Therapeutics's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Arrakis Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2025, Arrakis Therapeutics has approximately 84 employees across 4 continents, including North AmericaEuropeOceania. Key team members include Chief Executive Officer: M. G.Chief Business Officer: J. M.Chief Business Officer: D. K.. Explore Arrakis Therapeutics's employee directory with LeadIQ.

What industry does Arrakis Therapeutics belong to?

Minus sign iconPlus sign icon
Arrakis Therapeutics operates in the Pharmaceutical Manufacturing industry.

What technology does Arrakis Therapeutics use?

Minus sign iconPlus sign icon
Arrakis Therapeutics's tech stack includes CloudflareMixItUpjQuery UISlickMicrosoftMicrosoft ExchangeGoogle AnalyticsjQuery Waypoints.

What is Arrakis Therapeutics's email format?

Minus sign iconPlus sign icon
Arrakis Therapeutics's email format typically follows the pattern of FLast@arrakistx.com. Find more Arrakis Therapeutics email formats with LeadIQ.

How much funding has Arrakis Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2025, Arrakis Therapeutics has raised $113M in funding. The last funding round occurred on Apr 01, 2019 for $75M.

When was Arrakis Therapeutics founded?

Minus sign iconPlus sign icon
Arrakis Therapeutics was founded in 2015.
Arrakis Therapeutics

Arrakis Therapeutics

Pharmaceutical ManufacturingUnited States51-200 Employees

Arrakis has a simple but powerful vision: To extend small-molecule medicines into new realms of biology, unlocking that biology for medicine. Our approach builds on the existing sophisticated drug discovery toolkit developed for protein targets, which we are adapting and refocusing on discovering small-molecule compounds that act directly on RNA.

We are pioneering new territory, with an expedition led by a team of skilled scientists and drug development leaders who are inventive yet pragmatic. We are on a bold and exciting mission, a mission not without peril, but we have an energized, collaborative, creative and fearless team – a team that has consistently breached barriers and blazed new trails in search of solutions. We are now poised to realize the promise of bringing RNA into play for small-molecule drug discovery.

Pushing the frontier of this emerging field of science is gratifying, but our mission goes beyond the thrill of scientific discovery.  We believe that by targeting RNA biology in new ways, we have the potential to impact millions of patients.  Our platform will allow us to reach hundreds of biological targets not currently accessible to medicine, including known targets previously considered “undruggable.” Our destination is powerful new therapies for patients everywhere, by opening up a new path for discovering RNA-targeted medicines.

Section iconCompany Overview

Headquarters
828 Winter Street, Waltham, MA 02451, US
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2015
Employees
51-200

Section iconFunding & Financials

  • $113M

    Arrakis Therapeutics has raised a total of $113M of funding over 2 rounds. Their latest funding round was raised on Apr 01, 2019 in the amount of $75Mas a Series B.

  • $50M$100M

    Arrakis Therapeutics's revenue is estimated to be in the range of $50M$100M

Section iconFunding & Financials

  • $113M

    Arrakis Therapeutics has raised a total of $113M of funding over 2 rounds. Their latest funding round was raised on Apr 01, 2019 in the amount of $75Mas a Series B.

  • $50M$100M

    Arrakis Therapeutics's revenue is estimated to be in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.